GeneDx Holdings
Open
$63.18
Prev. Close
$63.18
High
$63.28
Low
$63.18
Market Snapshot
$1.82B
-86.5
-1.96
$305.45M
GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,300 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
emptyResult
GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,300 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
Recently from Cashu
GeneDx Holdings: Leading Innovation and Growth in the Genetic Testing Market
GeneDx Holdings: Pioneering Growth in Genetic Testing GeneDx Holdings stands out as a leading player in the rapidly expanding genetic testing industry, experiencing remarkable growth that reflects its…
GeneDx Holdings: Innovating Genetic Testing for a $40 Billion Market Opportunity
GeneDx: Leading the Charge in Genetic Testing Innovation GeneDx is rapidly establishing itself as a frontrunner in the genetic testing industry, showcasing remarkable growth and innovation. The compan…
GeneDx Holdings Launches ultraRapid Whole Genome Sequencing for Neonatal Care Enhancement
GeneDx Launches ultraRapid Whole Genome Sequencing for Neonatal Care GeneDx Holdings, a leader in genomic healthcare solutions, introduces its ultraRapid Whole Genome Sequencing service aimed at neona…
GeneDx Holdings Launches Rapid Genetic Testing to Transform Neonatal Healthcare
GeneDx Pioneers Rapid Genetic Testing for Neonatal Care GeneDx Holdings, a leader in genomic insights, is set to transform the landscape of neonatal and pediatric healthcare with the launch of its ult…